B · Normal
[Lukang Pharmaceutical: Obtained registration approval for imatinib mesylate tablets and API] On September 22, Lukang Pharmaceutical (600789.SH) announced that the company recently received the "Drug Registration Certificate" for imatinib mesylate tablets and the "Chemical API Marketing Application Approval Notice" for imatinib mesylate API issued by the State Food and Drug Administration. This drug is a protein tyrosine kinase inhibitor and is used to treat chronic myelogenous leukemia, etc. This approval enriches the company's product line of preparations and APIs and helps enhance market competitiveness.
A-share announcement express 🕐 2026-09-22 16:24
#Chemical #cell #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subje 09-22 17:43 [Tianchuang Fashion: Plans to change securities abbreviation to "Tianchuang Shar 09-22 17:34 [Honghe Technology: Shareholders reduced their holdings by 2.5% in total] On Sep 09-22 17:27 [Happy Home: The controlling shareholder plans to transfer 3.80% of the shares t 09-22 17:24 [Mingxin Xuteng: Shareholders holding more than 5% of the shares plan to transfe 09-22 17:21 [Yinglite: Temporary suspension of production of some production devices] On Sep 09-22 17:08

Comments

0/500
Captcha (click to refresh)
No comments yet